A5025732042- Cervical Cancer and HPV Research
- Adolescent Sexual and Reproductive Health
- Hepatitis B Virus Studies
- Vaccine Coverage and Hesitancy
- Genital Health and Disease
- Sexuality, Behavior, and Technology
- Child and Adolescent Health
- Reproductive tract infections research
- Gender, Feminism, and Media
- Adolescent and Pediatric Healthcare
- LGBTQ Health, Identity, and Policy
- Injury Epidemiology and Prevention
- Child and Adolescent Psychosocial and Emotional Development
- Sex work and related issues
- Child Development and Digital Technology
- Reproductive Health and Technologies
- Maternal Mental Health During Pregnancy and Postpartum
- Influenza Virus Research Studies
- Impact of Technology on Adolescents
- Psychiatric care and mental health services
- Primary Care and Health Outcomes
- Food Security and Health in Diverse Populations
- Traffic and Road Safety
- Global Cancer Incidence and Screening
- Digital Mental Health Interventions
The University of Sydney
2016-2025
Children's Hospital at Westmead
2016-2025
Sydney Children’s Hospitals Network
2019-2024
Taronga Conservation Society Australia
2022-2024
New South Wales Department of Health
2023
National Health and Medical Research Council
2023
Cardiff and Vale University Health Board
2023
Sydney Children's Hospital
2008-2021
The University of Western Australia
2003-2020
The Kids Research Institute Australia
2007-2019
Background. In April 2007, Australia became the first country to introduce a national government-funded human papillomavirus (HPV) vaccination program. We evaluated program's impact on genotype-specific HPV infection prevalence through repeat survey of women attending clinical services. Methods. genoprevalence in aged 18–24 years family planning clinics prevaccine period (2005–2007) was compared with among same age group postvaccine (2010–2011). The recruitment and testing strategies were...
The control arm of PATRICIA (PApilloma TRIal against Cancer In young Adults, NCT00122681) was used to investigate the risk progression from cervical HPV infection intraepithelial neoplasia (CIN) or clearance infection, and associated determinants.Women aged 15-25 years were enrolled. A 6-month persistent (6MPI) defined as detection same type at two consecutive evaluations over 6 months ≥2 type-specific negative samples taken intervals approximately following a positive sample. primary...
A quadrivalent human papillomavirus vaccination program targeting females aged 12-13 years commenced in Australia 2007, with catch-up of 14-26 year olds through 2009. We evaluated the program's impact on HPV prevalence among women 18-35 2015.HPV 18-24 and 25-35 was compared these age groups 2005-2007. For 18-24, we also that a postvaccine study conducted 2010-2012.For 2015 sample, Vaccination Register-confirmed 3-dose coverage 53.3% (65.0% 40.3% 25-35, respectively). Prevalence vaccine types...
In the Phase III PATRICIA study (NCT00122681), human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine (Cervarix(®), GlaxoSmithKline Biologicals) was highly efficacious against HPV-16/18 infections and precancerous lesions in women deoxyribose nucleic acid (DNA) negative seronegative at baseline. We present further data on efficacy (VE) total vaccinated cohort including who may have been exposed to infection before vaccination. with no evidence of current or previous (DNA seronegative), VE...
Injection using needle and syringe (N&S) is the most widely used method for vaccination, but requires trained healthcare workers. Fear of needles, risk needle-stick injury, need to reconstitute lyophilised vaccines, are also drawbacks. The Nanopatch (NP) a microarray skin patch comprised high-density array microprojections dry-coated with vaccine that being developed address these shortcomings. Here we report randomised, partly-blinded, placebo-controlled trial represents first use in humans...
ABSTRACT We report final event-driven analysis data on the immunogenicity and efficacy of human papillomavirus 16 18 ((HPV-16/18) AS04-adjuvanted vaccine in young women aged 15 to 25 years from PApilloma TRIal against Cancer In Adults (PATRICIA). The total vaccinated cohort (TVC) included all randomized participants who received at least one dose (vaccine, n = 9,319; control, 9,325) months 0, 1, and/or 6. TVC-naive 5,822; 5,819) had no evidence high-risk HPV infection baseline, approximating...
The control arm of the phase III VIVIANE (Human PapillomaVIrus: Vaccine Immunogenicity ANd Efficacy; NCT00294047) study in women >25 years was studied to assess risk progression from cervical HPV infection detectable intraepithelial neoplasia (CIN). detecting CIN associated with same type as reference analysed using Kaplan–Meier and multivariable Cox models. Infections were categorised depending upon persistence 6‐month persistent (6MPI) or any duration. 4‐year interim analysis included...
We evaluated the efficacy of human papillomavirus (HPV)−16/18 AS04‐adjuvanted vaccine in preventing HPV‐related disease after surgery for cervical lesions a post‐hoc analysis PApilloma TRIal against Cancer In young Adults (PATRICIA; NCT00122681). Healthy women aged 15–25 years were randomized (1:1) to receive or control at months 0, 1 and 6 followed 4 years. Women enrolled regardless their baseline HPV DNA status, HPV‐16/18 serostatus, cytology, but excluded if they had previous planned...
Internationally, vaccination rates among adolescents with intellectual and developmental disability (IDD) are lower than those of the general population. Little research has addressed this issue. This study investigates experiences vaccinating IDD in special education settings Australia, a focus on student engagement. Semistructured interviews groups were undertaken 50 stakeholders involved school program. Data was analyzed thematically using framework approach. We identified five themes:...
Background. Public Health England has reported a decrease of up to 20.8% in new diagnoses external genital warts (GWs) among women aged <19 years since the national vaccination program with human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine began 2008. A post hoc analysis phase III PATRICIA (PApilloma TRIal against Cancer In young Adults) trial (NCT00122681) was performed ascertain whether protection low-risk HPV types apparent. Methods. Vaccine efficacy (VE) at 48 months assessed...
We evaluated baseline data from the PApilloma TRIal against Cancer In young Adults (PATRICIA; NCT00122681) on association between behavioral risk factors and HPV infection cervical abnormalities.Women completed questionnaires at baseline. Prevalence of abnormalities (detected by cytological or histological procedures) with were analyzed univariate stepwise multivariable logistic regressions.16782 women questionnaires. Among 16748 for infection, 4059 (24.2%) infected any type. 16757...